JP2019533705A - 心筋梗塞の再構成された高密度リポタンパク質治療 - Google Patents

心筋梗塞の再構成された高密度リポタンパク質治療 Download PDF

Info

Publication number
JP2019533705A
JP2019533705A JP2019524144A JP2019524144A JP2019533705A JP 2019533705 A JP2019533705 A JP 2019533705A JP 2019524144 A JP2019524144 A JP 2019524144A JP 2019524144 A JP2019524144 A JP 2019524144A JP 2019533705 A JP2019533705 A JP 2019533705A
Authority
JP
Japan
Prior art keywords
rhdl
formulation
use according
rhdl formulation
apolipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533705A5 (OSRAM
Inventor
サミュエル・ライト
チャールズ・シアラー
デニス・ダンドレア
アンドレアス・ジル
ダニエル・ダフィ
Original Assignee
シーエスエル、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル、リミテッド filed Critical シーエスエル、リミテッド
Publication of JP2019533705A publication Critical patent/JP2019533705A/ja
Publication of JP2019533705A5 publication Critical patent/JP2019533705A5/ja
Priority to JP2022089334A priority Critical patent/JP7464654B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019524144A 2016-11-10 2017-11-10 心筋梗塞の再構成された高密度リポタンパク質治療 Pending JP2019533705A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022089334A JP7464654B2 (ja) 2016-11-10 2022-06-01 心筋梗塞の再構成された高密度リポタンパク質治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420050P 2016-11-10 2016-11-10
US62/420,050 2016-11-10
US201762472240P 2017-03-16 2017-03-16
US62/472,240 2017-03-16
PCT/AU2017/051232 WO2018085890A1 (en) 2016-11-10 2017-11-10 Reconstituted high density lipoprotein treatment of myocardial infarction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022089334A Division JP7464654B2 (ja) 2016-11-10 2022-06-01 心筋梗塞の再構成された高密度リポタンパク質治療

Publications (2)

Publication Number Publication Date
JP2019533705A true JP2019533705A (ja) 2019-11-21
JP2019533705A5 JP2019533705A5 (OSRAM) 2020-11-12

Family

ID=62109053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524144A Pending JP2019533705A (ja) 2016-11-10 2017-11-10 心筋梗塞の再構成された高密度リポタンパク質治療
JP2022089334A Active JP7464654B2 (ja) 2016-11-10 2022-06-01 心筋梗塞の再構成された高密度リポタンパク質治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022089334A Active JP7464654B2 (ja) 2016-11-10 2022-06-01 心筋梗塞の再構成された高密度リポタンパク質治療

Country Status (12)

Country Link
US (2) US20200038481A1 (OSRAM)
EP (1) EP3538105A4 (OSRAM)
JP (2) JP2019533705A (OSRAM)
KR (2) KR20190084095A (OSRAM)
CN (2) CN109922810A (OSRAM)
AU (2) AU2017358402B2 (OSRAM)
BR (1) BR112019007709A2 (OSRAM)
CA (1) CA3043110A1 (OSRAM)
IL (1) IL266428B2 (OSRAM)
MX (1) MX2019005459A (OSRAM)
SG (2) SG11201903945XA (OSRAM)
WO (1) WO2018085890A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017081561A1 (en) 2015-11-09 2017-05-18 Revamp Medical Ltd. Blood flow reducer for cardiovascular treatment
US12295580B2 (en) 2018-12-11 2025-05-13 Revamp Medical Ltd. Systems, devices, and methods for adjusting blood flow in a body lumen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529648A (ja) * 2010-06-30 2013-07-22 シーエスエル、リミテッド リポタンパク質製剤及びその製造方法
JP2015535263A (ja) * 2012-11-02 2015-12-10 シーエスエル、リミテッド 再構成されたｈｄｌ製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
CA2857968A1 (en) 2011-12-21 2013-06-27 Csl Limited Dosage regime for apolipoprotein formulations
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20160074473A1 (en) 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529648A (ja) * 2010-06-30 2013-07-22 シーエスエル、リミテッド リポタンパク質製剤及びその製造方法
JP2015535263A (ja) * 2012-11-02 2015-12-10 シーエスエル、リミテッド 再構成されたｈｄｌ製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM HEART J, OCTOBER 2016, VOL.180, PP.22-28, JPN6021024284, ISSN: 0004538524 *
ARTERIOSCLER THROMB VASC BIOL, 2013, NO.33, PP.2202-2211, JPN6021024282, ISSN: 0004538525 *

Also Published As

Publication number Publication date
SG10201911714YA (en) 2020-02-27
BR112019007709A2 (pt) 2019-07-09
US20200038481A1 (en) 2020-02-06
SG11201903945XA (en) 2019-05-30
WO2018085890A1 (en) 2018-05-17
IL266428A (en) 2019-06-30
EP3538105A1 (en) 2019-09-18
CN116196395A (zh) 2023-06-02
IL266428B1 (en) 2024-08-01
JP7464654B2 (ja) 2024-04-09
AU2017358402B2 (en) 2023-10-05
CA3043110A1 (en) 2018-05-17
MX2019005459A (es) 2019-08-12
AU2017358402A1 (en) 2019-04-18
KR20190084095A (ko) 2019-07-15
US20240207357A1 (en) 2024-06-27
AU2023282314A1 (en) 2024-01-18
CN109922810A (zh) 2019-06-21
KR20240044543A (ko) 2024-04-04
IL266428B2 (en) 2024-12-01
EP3538105A4 (en) 2020-05-20
RU2019117552A3 (OSRAM) 2021-06-25
JP2022116254A (ja) 2022-08-09
RU2019117552A (ru) 2020-12-10

Similar Documents

Publication Publication Date Title
von Eckardstein et al. High-density lipoprotein revisited: biological functions and clinical relevance
JP7605949B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
Palladini et al. Novel strategies for the diagnosis and treatment of cardiac amyloidosis
US20240207357A1 (en) Reconstituted high density lipoprotein treatment of myocardial infarction
Gibson et al. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein AI [human]), an intravenous formulation of plasma-derived apolipoprotein AI, among subjects with moderate renal impairment after acute myocardial infarction
JP6340372B2 (ja) 再構成されたｈｄｌ製剤
Durrington et al. Lipoprotein (a): gene genie
Raggi et al. Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Ortega-Paz et al. Clinical pharmacokinetics and pharmacodynamics of CSL112
Shemesh-Darvish et al. TV-1380 attenuates cocaine-induced changes in cardiodynamic parameters in monkeys and reduces the formation of cocaethylene
CN109789217A (zh) 用于降低脂蛋白颗粒对动脉壁酶引起的致动脉粥样硬化性聚集的敏感度的方法和试剂盒
Stefanutti et al. Treatment of symptomatic hyperLp (a) lipidemia with LDL-apheresis vs. usual care
Zheng et al. HDL infusion for the management of atherosclerosis: current developments and new directions
RU2798830C2 (ru) Лечение восстановленным липопротеином высокой плотности инфаркта миокарда
Kootte et al. Effect of open-label infusion of an apolipoprotein AI-containing particle (CER-001) on reverse cholesterol transport and artery wall thickness in patients with familial hypo-alphalipoproteinemia
US20200261549A1 (en) Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
WO2025210584A1 (en) Reconstituted high density lipoprotein treatment of myocardial infarction
RU2776110C2 (ru) Схема дозирования для составов аполипопротеина
Parhofer Controversial Issues in the Treatment of Dyslipidemias in Patients with Diabetes Mellitus
Louis Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?
Johnston et al. 1047-188 The ratio of oxidized low-density to high-density lipoproteins is an independent predictor of acute myocardial infarction in unstable coronary artery disease
Nicholls et al. Practical Approach to Diagnosis & Management of Lipid Disorders
US20070184486A1 (en) Diagnosis or treatment of endothelial cell dysfunction related diseases
Thompson et al. 44 Lipid management after a coronary

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201